Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Group 1 - The article discusses Verastem, Inc. (NASDAQ: VSTM) and its upcoming catalysts in 2024, particularly focusing on the NDA rolling submission of Defactinib [2] - The author is affiliated with Biotech Analysis Central, which provides extensive analysis on various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio [2] - The service offers a subscription model, with a monthly fee of $49 and an annual plan at a discounted rate of $399, which represents a 33.50% discount [1] Group 2 - The article does not provide any specific financial data or performance metrics related to Verastem, Inc. or the broader biotech industry [3][4]